LQDA
Liquidia Corp
NASDAQ · Healthcare · Biotechnology · US
$44.40
−0.20%Price chart
Oct 8Oct 13Oct 16Oct 21Oct 26Oct 29Nov 3Nov 6
Key dataNov 6, 2026
Open$44.60
From 52W high−51.22%
Volume1.29M
Market cap$3.97B
P/E (TTM)28.3x
P/S (TTM)8.8x
Div yield—
Key dataNov 6, 2026
Open
$44.60
From 52W high
−51.22%
Volume
1.29M
Market cap
$3.97B
ValuationView details →
P/E (Fwd)
48.2x
EV/EBITDA
21.5x
P/E (TTM)
28.3x
RSI (14)
51.2
MomentumView details →
1D Return
−0.20%
YTD Return
+29.08%
SummaryUpdated Jun 1, 2026
Liquidia Corporation (NASDAQ:LQDA) is a biopharmaceutical company founded in 2004 and headquartered in Morrisville, North Carolina. The company went public in July 2018 and focuses on developing and commercializing innovative treatments for rare diseases, particularly pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia utilizes its proprietary PRINT technology platform to create precisely engineered drug particles that can improve the delivery and efficacy of existing medications.
Similar companies
Latest newsMore news →
Liquidia Corp announced that it will report its third-quarter 2026 financial results on November 10, 2026, and host a live webcast at 8:30 a.m. Eastern Time to discuss the results and provide a corporate update.5d agoLiquidia Corp shares surged 25% to $33.47.24d agoLiquidia agreed to terminate its promotional agreement for treprostinil injection and stop supporting sales of the product in the market.25d ago